1h Free Analyst Time
According to the recently published report 'Catenin Beta 1 - Drugs In Development, 2022'; Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 23 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ß-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.
The report 'Catenin Beta 1 - Drugs In Development, 2022' outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.
Report covers products from therapy areas Oncology, Respiratory, Dermatology, Gastrointestinal, Infectious Disease and Non Malignant Disorders which include indications Colorectal Cancer, Breast Cancer, Liver Cancer, Solid Tumor, Hepatocellular Carcinoma, Melanoma, Unspecified Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Gastric Cancer, Idiopathic Pulmonary Fibrosis, Lung Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Thyroid Cancer, Bladder Cancer, Blood Cancer, Brain Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19), Endometrial Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gastrointestinal Tumor, Head And Neck Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Kidney Cancer (Renal Cell Cancer), Leukemia, Liver Cirrhosis, Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Scar and Small-Cell Lung Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
- Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
- 3+2 Pharma LLC
- Agastiya Biotech LLC
- Aileron Therapeutics Inc
- Circle Pharma Inc
- Dicerna Pharmaceuticals Inc
- Entrada Therapeutics Inc
- f5 Therapeutics Inc
- Fog Pharmaceuticals Inc
- iBeCa Therapeutics
- MD2 Biosciences Inc
- PRISM Pharma Co Ltd
- Propanc Biopharma Inc
- Sapience Therapeutics Inc
- Stemsynergy Therapeutics Inc
- Sumitomo Dainippon Pharma Oncology, Inc
- Venn Therapeutics LLC
- WntRx Pharmaceuticals Inc
- Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
- AB-01 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BBI-801 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Beta catenin Degrader Antibody - Drug Profile
- Product Description
- Mechanism Of Action
- Beta-Catenin Transcriptional Complex Inhibitors - Drug Profile
- Product Description
- Mechanism Of Action
- CBP/beta-Catenin Antagonist - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- exisulind - Drug Profile
- Product Description
- Mechanism Of Action
- FOG-001 - Drug Profile
- Product Description
- Mechanism Of Action
- nefopam hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Oligonucleotides for Hepatoblastoma - Drug Profile
- Product Description
- Mechanism Of Action
- PRI-724 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PRP - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit Beta Catenin for Colorectal Cancer and Brain Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CTNNB1 for Unspecified Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- ST-316 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Wnt-Driven Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- WNTinib - Drug Profile
- Product Description
- Mechanism Of Action
- WX-024 - Drug Profile
- Product Description
- Mechanism Of Action
- Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
- Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
- Featured News & Press Releases
- Sep 08, 2022: Propanc Biopharma reports significant effects of PRP against the tumor microenvironment
- Aug 23, 2022: Propanc Biopharma synthesizes recombinant trypsinogen & chymotrypsinogen via POP1 joint research & drug discovery program
- Jul 28, 2022: Propanc Biopharma’s CSO reflects on unique anti-cancer effects of PRP discovered over past decade
- Jul 12, 2022: Propanc Biopharma’s CEO believes lead asset could unlock value as PRP advances to phase I, first-in-human study in advanced cancer patients
- Jul 05, 2022: Propanc Biopharma’s CEO comments on the 39 granted patents and 26 patent applications under examination in key global jurisdictions
- Jun 22, 2022: Propanc Biopharma’s CSO hails dostarlimab’s impressive results whilst acknowledging more work to be done in the fight against cancer
- Jun 01, 2022: Propanc Biopharma believes PRP reduced toxicity will impact cancer patient lives significantly
- May 26, 2022: Propanc Biopharma presents 100 years of clinical evidence for “novel” enzyme therapeutic approach to treat cancer
- May 18, 2022: Propanc Biopharma undertaking PRP manufacturing & development for human use
- May 11, 2022: Propanc Biopharma offers a novel way to stop cancer
- May 03, 2022: Agastiya Biotech receives FDA Orphan Drug Designation for AB001 for pancreatic cancer and Acute Myeloid Leukemia (AML)
- May 02, 2022: Propanc Biopharma purchases pharma grade raw materials for PRP manufacture in preparation for phase I first-in-human study
- Apr 13, 2022: Propanc Biopharma’s management explains why they believe cancer patients are likely to respond to PRP treatment
- Apr 11, 2022: Sapience Therapeutics presents late-breaking data on ST316 at AACR 2022
- Mar 22, 2022: Propanc Biopharma receives notice of allowance for method to treat cancer stem cells from the US Patent & Trademark Office
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dormant Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3+2 Pharma LLC
- Agastiya Biotech LLC
- Aileron Therapeutics Inc
- Circle Pharma Inc
- Dicerna Pharmaceuticals Inc
- Entrada Therapeutics Inc
- f5 Therapeutics Inc
- Fog Pharmaceuticals Inc
- iBeCa Therapeutics
- MD2 Biosciences Inc
- PRISM Pharma Co Ltd
- Propanc Biopharma Inc
- Sapience Therapeutics Inc
- Stemsynergy Therapeutics Inc
- Sumitomo Dainippon Pharma Oncology, Inc
- Venn Therapeutics LLC
- WntRx Pharmaceuticals Inc
